ProSkelia Overview
- Founded
-
2002
- Status
-
Acquired/Merged
- Employees
-
65
- Latest Deal Type
-
M&A
- Financing Rounds
-
3
ProSkelia General Information
Description
Provider of drug discovery and development intended to treat bone diseases. The company's portfolio of technology includes an exclusive program named oestradiol glucoside ("E2G"), which completed a Phase IIa clinical study for the treatment of menopausal symptoms, along with drugs related to the preclinical development and in vivo pharmacology.
Contact Information
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Biotechnology
Acquirer
Primary Office
- 102 route de Noisy
- 93230 Romainville
- France
ProSkelia Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ProSkelia Patents
ProSkelia Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20040265808-A1 | Diagnosing osteoporosis by analyzing the gene expression of given nucleotide sequence in sample; detecting amplified cdna | Inactive | 05-Apr-2001 | 000000000 |
ProSkelia Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
ProSkelia Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|